Basilea Pharmaceutica AG (SWX:BSLN)
64.60
-1.00 (-1.52%)
Aug 21, 2026, 5:31 PM CET
Basilea Pharmaceutica AG Revenue
Basilea Pharmaceutica AG had revenue of 119.00M CHF in the half year ending June 30, 2026, with 55.97% growth. This brings the company's revenue in the last twelve months to 247.42M, up 4.74% year-over-year. In the year 2025, Basilea Pharmaceutica AG had annual revenue of 232.38M with 11.43% growth.
Revenue (ttm)
247.42M
Revenue Growth
+4.74%
P/S Ratio
3.24
Revenue / Employee
1.24M
Employees
200
Market Cap
801.24M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 232.38M | 23.84M | 11.43% |
| Dec 31, 2024 | 208.54M | 50.91M | 32.30% |
| Dec 31, 2023 | 157.63M | 9.87M | 6.68% |
| Dec 31, 2022 | 147.77M | -357.00K | -0.24% |
| Dec 31, 2021 | 148.12M | 20.49M | 16.06% |
| Dec 31, 2020 | 127.63M | -6.75M | -5.02% |
| Dec 31, 2019 | 134.38M | 1.83M | 1.38% |
| Dec 31, 2018 | 132.56M | 31.03M | 30.57% |
| Dec 31, 2017 | 101.52M | 35.54M | 53.86% |
| Dec 31, 2016 | 65.98M | 13.16M | 24.91% |
| Dec 31, 2015 | 52.83M | 10.19M | 23.90% |
| Dec 31, 2014 | 42.63M | 1.26M | 3.04% |
| Dec 31, 2013 | 41.38M | -16.96M | -29.07% |
| Dec 31, 2012 | 58.34M | -8.51M | -12.73% |
| Dec 31, 2011 | 66.85M | -176.32M | -72.51% |
| Dec 31, 2010 | 243.17M | 216.34M | 806.40% |
| Dec 31, 2009 | 26.83M | 14.85M | 124.05% |
| Dec 31, 2008 | 11.97M | 3.76M | 45.82% |
| Dec 31, 2007 | 8.21M | -6.37M | -43.68% |
| Dec 31, 2006 | 14.58M | -15.91M | -52.18% |
| Dec 31, 2005 | 30.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bachem Holding AG | 708.53M |
| Idorsia | 199.71M |
| Santhera Pharmaceuticals Holding AG | 77.19M |
| Newron Pharmaceuticals | 17.81M |
| BioVersys AG | 3.18M |
| Molecular Partners AG | 681.00K |
| MindMaze Therapeutics Holding | 642.00K |
| Xlife Sciences AG | 275.31K |
Basilea Pharmaceutica AG News
- 4 days ago - Basilea Pharmaceutica AG Earnings Call Transcript: H1 2026 - Transcripts
- 4 days ago - Basilea Pharmaceutica AG Quarterly report: H1 2026 - Filings
- 4 days ago - Basilea Pharmaceutica AG Slides: H1 2026 - Filings
- 4 days ago - Basilea Pharmaceutica AG Earnings release: H1 2026 - Filings
- 17 days ago - Basilea Pharmaceutica AG Slides: Investor presentation - Filings
- 17 days ago - Basilea Receives BARDA Funding Of $5.4 Mln To Advance Antibiotic Combination In Treating UTIs - Nasdaq
- 24 days ago - Basilea Secures Fresh BARDA Support With $30M Tranche For Phase 3 Antifungal Fosmanogepix - Nasdaq
- 7 weeks ago - Basilea Pharmaceutica AG Slides: Investor presentation - Filings